Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.

Abstract

PURPOSE We hypothesized that common polymorphisms in excision repair cross-complementation group 1 (ERCC1), involved in nucleotide excision repair of platinum-induced damage, would be associated with progression-free survival (PFS) and overall survival (OS) in women with optimally resected, stage III epithelial ovarian cancer (EOC) treated with cisplatin… (More)
DOI: 10.1200/JCO.2008.16.1323

Topics

Cite this paper

@article{Krivak2008RelationshipBE, title={Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.}, author={Thomas Carl Krivak and Kathleen M. Darcy and Chunqiao Q. Tian and Deborah Armstrong and Bora E. Baysal and Holly Gallion and Christine B. Ambrosone and Julie A Deloia}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2008}, volume={26 21}, pages={3598-606} }